Linked Data API

Show Search Form

Search Results

627291
registered interest false more like this
date less than 2016-11-02more like thismore than 2016-11-02
answering body
Ministry of Defence more like this
answering dept id 11 more like this
answering dept short name Defence more like this
answering dept sort name Defence more like this
hansard heading Armed Forces: Redundancy more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Defence, how many (a) Army, (b) Royal Air Force and (c) Royal Navy officers who had served for more than 12 but fewer than 16 years were made compulsorily redundant during the four tranches of redundancies from September 2011 to June 2014. more like this
tabling member constituency Bristol West more like this
tabling member printed
Thangam Debbonaire remove filter
uin 51540 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2016-11-08more like thismore than 2016-11-08
answer text <p>The requested information is provided below:</p><p> </p><p> </p><p><strong>Involuntary Redundancies September 2011 – June 2014, UK Regular Armed Forces Officers with 13-15 years of service</strong></p><table><tbody><tr><td><p>Royal Navy</p></td><td><p>10</p></td></tr><tr><td><p>Army</p></td><td><p>30</p></td></tr><tr><td><p>Royal Air Force</p></td><td><p>30</p></td></tr></tbody></table><p> </p><p>Notes: Figures for UK Regular Service Officers include Nursing Services, but exclude Full Time Reserve Service personnel, Gurkhas, mobilised Reservists, Military Provost Guard Service, Locally Engaged Personnel, Non Regular Permanent Staff, High Readiness Reserve and Expeditionary Forces Institute personnel. All figures are rounded to the nearest 10.</p> more like this
answering member constituency Milton Keynes North more like this
answering member printed Mark Lancaster more like this
question first answered
less than 2016-11-08T16:06:23.65Zmore like thismore than 2016-11-08T16:06:23.65Z
answering member
1544
label Biography information for Lord Lancaster of Kimbolton more like this
tabling member
4433
label Biography information for Thangam Debbonaire more like this
626585
registered interest false more like this
date less than 2016-11-01more like thismore than 2016-11-01
answering body
Department for Education more like this
answering dept id 60 more like this
answering dept short name Education more like this
answering dept sort name Education more like this
hansard heading Universities: Competition more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Education, what steps she is taking to ensure that UK universities remain globally competitive after the UK leaves the EU. more like this
tabling member constituency Bristol West more like this
tabling member printed
Thangam Debbonaire remove filter
uin 51362 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2016-11-04more like thismore than 2016-11-04
answer text <p>UK universities are home to both world-class teaching and life-changing research, and exiting the EU will not change this. The Government has already announced that EU students applying for a place at an English university or further education institution in 2017/2018 (or before) will continue to be eligible for student loans and grants for the duration of their course, even if the UK exits the EU during that period. To support research and innovation, we have also announced that HM Treasury will underwrite funding for approved Horizon 2020 projects applied for before the UK leaves the EU, including where specific projects continue beyond the UK’s departure.</p><p>Future arrangements for EU students and staff, funding and also UK students studying abroad will need to be considered as part of wider discussions about the UK’s relationship with the EU. The Government is fully committed to ensuring that we get the best possible outcome for the higher education sector from its negotiations with the EU.</p>
answering member constituency Orpington more like this
answering member printed Joseph Johnson more like this
question first answered
less than 2016-11-04T13:18:03.877Zmore like thismore than 2016-11-04T13:18:03.877Z
answering member
4039
label Biography information for Lord Johnson of Marylebone more like this
tabling member
4433
label Biography information for Thangam Debbonaire more like this
626637
registered interest false more like this
date less than 2016-11-01more like thismore than 2016-11-01
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Nivolumab more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, pursuant to the Answer of 27 June 2014 to Question 40281, on what date he expects NICE to publish the results of the consultation on the guidance on the use of nivolumab for the treatment of lung cancer. more like this
tabling member constituency Bristol West more like this
tabling member printed
Thangam Debbonaire remove filter
uin 51363 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2016-11-04more like thismore than 2016-11-04
answer text <p>The National Institute for Health and Care Excellence (NICE) is currently carrying out two separate technology appraisals of nivolumab (Opdivo) for previously treated locally advanced or metastatic non-squamous non-small cell lung cancer and previously treated locally advanced or metastatic squamous non-small-cell lung cancer after prior chemotherapy in adults.</p><p> </p><p>NICE is currently consulting on draft guidance for both appraisals and the closing date for comments is 4 November 2016. Subsequent timescales for guidance development are yet to be confirmed by NICE. NICE will publish comments received in response to the consultation and its responses alongside the next iteration of its draft guidance.</p> more like this
answering member constituency Oxford West and Abingdon more like this
answering member printed Nicola Blackwood more like this
question first answered
less than 2016-11-04T10:38:53.477Zmore like thismore than 2016-11-04T10:38:53.477Z
answering member
4019
label Biography information for Baroness Blackwood of North Oxford more like this
tabling member
4433
label Biography information for Thangam Debbonaire more like this
626753
registered interest false more like this
date less than 2016-11-01more like thismore than 2016-11-01
answering body
Department for Business, Energy and Industrial Strategy more like this
answering dept id 201 more like this
answering dept short name Business, Energy and Industrial Strategy more like this
answering dept sort name Business, Energy and Industrial Strategy more like this
hansard heading Intellectual Property: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Business, Energy and Industrial Strategy, what his Department's policy is on using the flexibility provided by the Trade Related Aspects of Intellectual Property Rights under World Trade Organisation rules for compulsory license for the Kadcyla form of trastuzumab emtansine for UK patients. more like this
tabling member constituency Bristol West more like this
tabling member printed
Thangam Debbonaire remove filter
uin 51439 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2016-11-04more like thismore than 2016-11-04
answer text <p>The UK Patents Act 1977, in line with the WTO TRIPS Agreement, provides for compulsory licenses in certain circumstances.</p><p> </p><p>Kadcyla (trastuzumab emtansine) is currently available to patients in England for the treatment of HER2-positive locally advanced, unresectable or metastatic breast cancer through the Cancer Drugs Fund.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is currently reviewing its technology appraisal guidance on trastuzumab emtansine for refractory, HER2 positive breast cancer. NICE expects to publish its updated guidance in February 2017.</p><p> </p> more like this
answering member constituency Orpington more like this
answering member printed Joseph Johnson more like this
question first answered
less than 2016-11-04T14:03:54.493Zmore like thismore than 2016-11-04T14:03:54.493Z
answering member
4039
label Biography information for Lord Johnson of Marylebone more like this
tabling member
4433
label Biography information for Thangam Debbonaire more like this